Neurosense Therapeutics News - August 31, 2026
NeuroSense Fast-Tracks PrimeC Development, Cutting Costs for ALS Drug Approval
NeuroSense Therapeutics has redesigned its development plan for PrimeC to treat amyotrophic lateral sclerosis (ALS). The new strategy replaces a single large...
🟢 Neurosense Therapeutics is trading 13.23% up today in pre-market; catalyst remains unclear
Neurosense Therapeutics is trading 13.23% higher at $0.48 after rising from the August 28 close of $0.42, with no clear catalyst identified. - No fresh...
🟢 Neurosense Therapeutics is trading 7% up in pre-market with no clear catalyst identified
Neurosense Therapeutics is trading 7.04% up at $0.45, with no fresh company-specific announcement for August 31, 2026 identified. - It reached $0.42 at the...